BookR: School of Health Core Facilities Booking
PubMed Publications| Keyword search (4,163 papers available) |  |
"Stanga D" Authored Publications:
| Title | Authors | PubMed ID | |
|---|---|---|---|
| 1 | A Spike-Accum bioconjugate protein vaccine confers potent SARS-CoV-2-specific immunity | Pierre Bikorimana J; Caveney NA; El-Hachem N; Mandl GA; Capobianco JA; Stanga D; Abusarah J; Hancock MA; Farah R; Gonçalves MP; Falzarano D; Liao M; Hamonic G; Liu Q; Beaudoin S; Talbot S; Rafei M; | 41054531 CNSR |
| 2 | Publisher Correction: Characterization of three TRAPPC11 variants suggests a critical role for the extreme carboxy terminus of the protein. | Milev MP; Stanga D; Schänzer A; Nascimento A; Saint-Dic D; Ortez C; Natera-de Benito D; Barrios DG; Colomer J; Badosa C; Jou C; Gallano P; Gonzalez-Quereda L; Töpf A; Johnson K; Straub V; Hahn A; Sacher M; Jimenez-Mallebrera C; | 33173071 BIOLOGY |
| 3 | TRAPPing a neurological disorder: from yeast to humans. | Lipatova Z, Van Bergen N, Stanga D, Sacher M, Christodoulou J, Segev N | 32116085 BIOLOGY |
| 4 | Deficiencies in vesicular transport mediated by TRAPPC4 are associated with severe syndromic intellectual disability. | Van Bergen NJ, Guo Y, Al-Deri N, Lipatova Z, Stanga D, Zhao S, Murtazina R, Gyurkovska V, Pehlivan D, Mitani T, Gezdirici A, Antony J, Collins F, Willis MJH, Coban Akdemir ZH, Liu P, Punetha J, Hunter JV, Jhangiani SN, Fatih JM, Rosenfeld JA, Posey JE, Gibbs RA, Karaca E, Massey S, Ranasinghe TG, Sleiman P, Troedson C, Lupski JR, Sacher M, Segev N, Hakonarson H, Christodoulou J | 31794024 BIOLOGY |
| 5 | Characterization of three TRAPPC11 variants suggests a critical role for the extreme carboxy terminus of the protein. | Milev MP, Stanga D, Schänzer A, Nascimento A, Saint-Dic D, Ortez C, Benito DN, Barrios DG, Colomer J, Badosa C, Jou C, Gallano P, Gonzalez-Quereda L, Töpf A, Johnson K, Straub V, Hahn A, Sacher M, Jimenez-Mallebrera C | 31575891 BIOLOGY |
| 6 | Bi-allelic mutations in TRAPPC2L result in a neurodevelopmental disorder and have an impact on RAB11 in fibroblasts. | Milev MP, Graziano C, Karall D, Kuper WFE, Al-Deri N, Cordelli DM, Haack TB, Danhauser K, Iuso A, Palombo F, Pippucci T, Prokisch H, Saint-Dic D, Seri M, Stanga D, Cenacchi G, van Gassen KLI, Zschocke J, Fauth C, Mayr JA, Sacher M, van Hasselt PM | 30120216 BIOLOGY |
| 7 | TRAPPC11 functions in autophagy by recruiting ATG2B-WIPI4/WDR45 to preautophagosomal membranes. | Stanga D, Zhao Q, Milev MP, Saint-Dic D, Jimenez-Mallebrera C, Sacher M | 30843302 CONCORDIA |
| Title: | A Spike-Accum bioconjugate protein vaccine confers potent SARS-CoV-2-specific immunity | ||||
| Authors: | Pierre Bikorimana J, Caveney NA, El-Hachem N, Mandl GA, Capobianco JA, Stanga D, Abusarah J, Hancock MA, Farah R, Gonçalves MP, Falzarano D, Liao M, Hamonic G, Liu Q, Beaudoin S, Talbot S, Rafei M | ||||
| Link: | https://pubmed.ncbi.nlm.nih.gov/41054531/ | ||||
| DOI: | 10.1016/j.isci.2025.113314 | ||||
| Publication: | iScience | ||||
| Keywords: | Biological sciences; Immune response; Immunology; Natural sciences; | ||||
| PMID: | 41054531 | Category: | Date Added: | 2025-10-07 | |
| Dept Affiliation: |
CNSR
1 Department of Microbiology, Infectious Diseases, and Immunology, Université de Montréal, Montreal, QC H3T 1J4, Canada. 2 Centre for Blood Research, University of British Columbia, Vancouver, BC V6T 1Z3, Canada. 3 Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON M5S 1A8, Canada. 4 Sainte-Justine Research Centre, Montreal, QC H3T 1C5, Canada. 5 Department of Chemistry and Biochemistry and Centre for NanoScience Research, Concordia University, Montreal, QC H3T 1J4, Canada. 6 Research and Development Branch, Defence Therapeutics Inc., Montreal, QC H4S 1Z9, Canada. 7 Department of Pharmacology and Physiology, Université de Montréal, Montreal, QC H3T 1J4, Canada. 8 SPR-MS Facility, Department of Pharmacology and Therapeutics, McGill University, Montreal, QC H3G 1Y6, Canada. 9 Vaccine and Infectious Disease Organization, University of Saskatchewan, Saskatoon, SK S7N 5E3, Canada. 10 Department of Biomedical & Molecular Sciences, Queen's University, Kingston, ON K7L 3J8, Canada. 11 Molecular Biology Program, Université de Montréal, Montreal, QC H3T 1J4, Canada. |
||||
Description: |
Despite the recent control of COVID-19, the devastating effects caused by the 3-year pandemic highlight the importance of developing effective vaccines to rapidly address future outbreaks. The present study describes a novel Spike (Sp) protein-based vaccine formulation using the Accum platform. Although Sp-Accum bioconjugation does not alter the overall protein structure, it triggers a substantial antibody titer: i) exhibiting higher specificity toward the S1 domain of Sp, ii) neutralizing Sp-ACE2 interactions, and iii) cross-reacting with various Sp variants. Besides validating the vaccine immunogenicity in rabbits, its administration in a "gold-standard" SARS-CoV-2 hamster model was shown to be safe while accelerating viral clearance without eliciting signs of pathological inflammation in the lungs of infected animals. Altogether, this proof-of-concept study not only demonstrates once again the versatility of the Accum technology in vaccine engineering, but it provides an enabling technology for the rapid development of value-added, protein-based vaccines for future pandemics. |
